Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Schwaab, T; Schwarzer, A; Wolf, B; Crocenzi, TS; Seigne, JD; Crosby, NA; Cole, BF; Fisher, JL; Uhlenhake, JC; Mellinger, D; Foster, C; Szczepiorkowski, ZM; Webber, SM; Schned, AR; Harris, RD; Barth, RJ; Heaney, JA; Noelle, RJ; Ernstoff, MS

doi:10.1158/1078-0432.ccr-08-3240

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Details

Request a copy

Serval ID

serval:BIB_6D9AE5F9A769

Type

Article: article from journal or magazin.

Collection

Publications

Institution

Production externe

Title

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Journal

Clinical Cancer Research

Author(s)

Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ, Heaney JA, Noelle RJ, Ernstoff MS

Publication state

Published

Issued date

08/2009

Language

english

DOI

10.1158/1078-0432.ccr-08-3240

Pubmed

19622576

Publisher's website

http://europepmc.org/abstract/med/19622576

Create date

13/09/2022 8:50

Last modification date

14/09/2022 6:37

Usage data

SERVAL

serveur académique lausannois

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Details